Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan
NCT00249977
Completed
1. To determine the safety and feasibility of administering Capecitabine with the combination of Cisplatin and Irinotecan. 2. To determine the Phase II recommended dose and toxicity profile of Capecitabine with the combination of Cisplatin and Irinotecan. 3. To study the biologic effect of pyrimidine inhibition on DNA repair after camptothecin therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2010
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Solid Tumors, Cancer
Register for Updates
Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
NCT00320983
Completed
A Phase I Study of Adjuvant Topotecan and Cisplatin with Concurrent Radiation Therapy for Advanced Cervical Cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/06/2010
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Cervical Cancer
Register for Updates
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
NCT00165139
Completed
The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by peripheral blood progenitor cells (stem cells), for children with advanced stage neuroblastoma and sarcomas.
Gender:
ALL
Ages:
19 years and below
Trial Updated:
10/30/2009
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Neuroblastoma, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
Register for Updates
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT00402545
Completed
The purpose of this research study is to determine the safest and most effective dose of 5-FU that can be given with docetaxel (Taxotere), Cisplatin and cetuximab to patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. We will also be studying the toxicity of this regimen of 4 drugs and the tumor response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2009
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Head and Neck Neoplasms
Register for Updates
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00053105
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/04/2009
Locations: Arizona Clinical Research Center, Tucson, Arizona +6 locations
Conditions: Lymphoma
Register for Updates
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
NCT00069966
Unknown
RATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone, and cisplatin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed aggressive non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2009
Locations: Arizona Oncology Associates - Craycroft Road Offices, Tucson, Arizona +28 locations
Conditions: Lymphoma
Register for Updates
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
NCT00229723
Completed
The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms of local disease control (progression-free) rate at 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2009
Locations: Research Site, Aurora, Colorado +24 locations
Conditions: Neoplasms, Squamous Cell
Register for Updates
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
NCT00004086
Unknown
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or deliver cancer killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2009
Locations: Garden State Cancer Center, Belleville, New Jersey
Conditions: Leukemia, Lymphoma
Register for Updates
Therapy for Children With Advanced Stage High Risk Neuroblastoma
NCT00186849
Completed
This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront window of two cycles of intravenous topotecan. We hypothesize that the topotecan window will be an effective therapy in terms of the response rate.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/19/2009
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates
Trial of Chemotherapy Followed by Pulsed Docetaxel and Concurrent Radiation for Non-Small Cell Lung Cancer
NCT00167401
Completed
The University of Rochester Cancer Center (URCC) is conducting a research study at Highland Hospital and Strong Memorial of lung cancer patients whose tumors cannot be surgically removed. The usual treatment for this stage of cancer is chemotherapy (treatment with drugs) combined with radiation (chemo-radiation). Because of the risk of spread to other organs, patients with your stage of disease are also often treated with additional chemotherapy, either before or after the chemo-radiation treatm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2009
Locations: University of Rochester, Dept. Radiation Oncology, Rochester, New York
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
NCT00087698
Completed
This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2009
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California +6 locations
Conditions: Pleural Neoplasms
Register for Updates
Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer
NCT00004063
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Combining hyperthermia with chemotherapy and interferon alfa may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of cisplatin, gemcitabine, interferon alfa, and whole-body hyperthermi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2009
Locations: University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates